Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. (Nasdaq: WGS), commonly referred to as GeneDx, regularly issues news focused on rare disease genomics, clinical impact, and corporate developments. The company describes itself as the global leader in rare disease diagnosis and a pioneer in genomic medicine, emphasizing the role of exome and genome sequencing and its GeneDx Infinity dataset in transforming care.
News updates from GeneDx often highlight financial results and guidance, including revenue trends, exome and genome test volumes, and margin profiles, alongside commentary on how these metrics relate to the company’s growth in genomic testing. Earnings releases may be accompanied by details on conference calls and investor presentations.
GeneDx also publishes frequent announcements on scientific and clinical milestones. These include peer‑reviewed publications, participation in large genomic newborn screening programs such as GUARDIAN and BEACONS, and recognition of its research by major medical journals. The company’s news flow covers conference presentations, advances in rapid genome sequencing, and developments in long‑read sequencing and gene–disease discovery.
Additional news items describe new test offerings like GenomeDx Prenatal, leadership appointments in medical and business roles, and partnerships such as the collaboration with Komodo Health to link GeneDx Infinity with real‑world healthcare data. For readers following WGS, this news page provides a centralized view of GeneDx’s financial disclosures, research output, clinical initiatives, and strategic collaborations in rare disease genomics.
Summary not available.
GeneDx (Nasdaq: WGS), a leader in genomic and clinical insights, has announced it will release its financial results for Q1 2023 on May 9, 2023, after market close. The event will include a conference call at 4:30 p.m. ET, hosted by President Katherine Stueland and CFO Kevin Feeley. Investors can register online to participate in the call, with both live and archived webcasts available on the GeneDx investor relations website.
GeneDx focuses on providing personalized health insights that inform diagnoses and treatment options, utilizing one of the largest rare disease data sets to support precision medicine. The company's efforts aim to enhance drug discovery and advance healthcare standards.
GeneDx (Nasdaq: WGS) announced the appointment of Devin K. Schaffer as General Counsel, effective April 24, 2023. Schaffer, with 15 years of legal experience, previously held leadership roles at Cardinal Health. As General Counsel, he will oversee all legal, compliance, and regulatory aspects for GeneDx. Katherine Stueland, President and CEO, expressed enthusiasm for Schaffer's addition to the executive leadership team, highlighting his ability to solve complex problems. His expertise aligns with GeneDx’s mission to enhance genomic insights and expand their healthcare offerings.
GeneDx Holdings Corp (Nasdaq: WGS) announced progress in the GUARDIAN study, which is screening 100,000 newborns for over 250 genetic conditions. To date, 1,000 newborns have been enrolled, with 2.6% showing true positive results for rare genetic disorders not part of standard newborn screening. The data presented at the ACMG Annual Meeting highlight the importance of whole genome sequencing (WGS) in early diagnosis, which could save approximately $30,000 per case by reducing unnecessary NICU care. GeneDx aims to make genomic sequencing a standard practice for newborn screening.
GeneDx Holdings Corp. (Nasdaq: WGS) announced significant findings at the ACMG Annual Clinical Genetics Meeting, highlighting the enhanced effectiveness of exome sequencing in reducing diagnostic delays. The research analyzed data from over 8,000 patients, revealing a 93.4% detection rate of copy number variants (CNVs) through exome sequencing, outperforming chromosomal microarray (CMA) tests. Notably, exome sequencing identified CNVs in 1.3% of CMA-negative cases, emphasizing its superiority. With the largest rare disease dataset, GeneDx aims to streamline diagnostics for congenital anomalies, developmental delays, and intellectual disabilities, positioning exome sequencing as the first-tier testing method.
GeneDx Holdings Corp. (Nasdaq: WGS) reported its 2022 financial results, showing pro forma revenues from continuing operations increased by 32% year-over-year to $45.8 million for Q4 2022 and 38% to $171 million for the full year. The company reiterated its 2023 guidance of $205-220 million in revenue and plans to achieve profitability by 2025. Despite a net operating loss of $324.8 million for Q4 2022 and $667.6 million for the full year, GeneDx expressed confidence in its growth strategy targeting pediatric rare diseases and enhancing genomic sequence analysis. The company closed a public offering in January 2023, raising $150 million.
GeneDx (Nasdaq: WGS) announced participation in the Cowen 43rd Annual Healthcare Conference on March 7, 2023, in Boston, MA. CEO Katherine Stueland will engage in a fireside chat at 2:50 p.m. ET. The event is expected to highlight the company’s advancements in genomic and clinical insights aimed at enhancing health outcomes.
A live and archived webcast of the discussion will be accessible through the 'Events' section of the GeneDx investor relations website. GeneDx specializes in precision medicine, utilizing genomic data to improve diagnosis and treatment options. For further information, visit the GeneDx website.
Summary not available.
GeneDx (Nasdaq: WGS) will report its financial results for Q4 and full year 2022 on March 14, 2023, after the market closes. A conference call featuring CEO Katherine Stueland and CFO Kevin Feeley will follow at 4:30 PM ET to discuss the company's financial and operational performance. GeneDx specializes in genomic and clinical insights, aiming to enhance health outcomes via precision medicine. The company is well-positioned in the healthcare sector, leveraging extensive rare disease data for its genomic testing and interpretation services.
GeneDx Holdings Corp. (Nasdaq: WGS) has published research in Nature Genetics, highlighting the significance of genetic insights in drug discovery. The study focuses on two-pore-domain potassium channels in rare diseases, particularly a newly identified condition linked to sleep apnea. Sleep apnea affects around 30 million Americans and poses a major health issue. The findings may lead to new therapeutic options for both the rare condition and common sleep apnea. GeneDx aims to leverage its extensive genomic data to enhance drug development and improve patient outcomes by connecting with biopharmaceutical companies.